Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Natco Pharma Ltd

NATCOPHARM.NS ✓ COMPLIANT ☆ Track — members

NSE India · Healthcare · Pharmaceuticals ·

India Small Cap Analyst: HOLD

Last Close

$9.08

▼ -2.01%

Market Cap $1.62B · Vol 443.47K

Key Metrics

P/E Ratio

13.56

FWD: 19.19

Market Cap

$1.62B

Small Cap

Div Yield

0.52%

Quarterly dividend

EPS Growth

-47.00%

YoY

RSI (14)

35.69

Momentum

Beta

0.86

vs Market

52W High

$12.86

29.65% below

52W Low

$8.27

3.62% above

Volume

443.47K

Avg 430.01K

P/B

1.89

Price-to-book

ROE

16.86%

Return on equity

Free Float

49.02%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Natco Pharma Ltd (NATCOPHARM.NS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NATCOPHARM.NS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-3.57%

-5.99%

-26.15%

-11.44%

YTD

-4.08%

-0.98%

-15.16%

-7.16%

Financials & Valuation

TTM · Annual

Total Revenue	$436.38M
Net Income	$146.79M
Revenue Growth (YoY)	-44.68%
Gross Margin	78.00%
Operating Margin	30.16%
Net Profit Margin	34.78%
ROE	16.86%
ROA · ROIC	15.13% · 16.29%

P/E Ratio	13.56
Forward P/E (FY1)	19.19
PEG Ratio	-0.50
P/S	4.28
P/B	1.89
P/FCF	10.73
EPS Growth	-47.00%
Outstanding Shares	179.11M

Technical Indicators

50-Day SMA	$9.65
200-Day SMA	$9.89
RSI (14)	35.69
Beta	0.86
52-Week High	$12.86
52-Week Low	$8.27

Volume Today	443.47K
Avg Daily Volume (30D)	430.01K
Relative Volume	1.03x
Volatility (10D)	35.97
Volatility (30D)	25.24
Free Float	49.02%

Analyst Consensus

HOLD

Current Price $9.08

Mean Target $10.48

52W Low$8.27 52W High$12.86

Current

Target

$8.27 $12.86

Current Analyst target

+15.40% upside potential · 10 analysts

Identifiers

ExchangeNSE India

FIGIBBG001S8GY34

ISININE987B01026

CountryIndia

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LLY Eli Lilly and Co -1.06% JNJ Johnson & Johnson +0.04% ABBV Abbvie Inc +0.48% NVS Novartis AG +1.24% NOVN.S Novartis AG +1.25%

Company Profile

Natco Pharma Limited is an India-based vertically integrated pharmaceutical company with a focus on research and development. It develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. Its segments include Pharmaceuticals and Agro chemicals. The Pharmaceuticals segment is engaged in the manufacturing and selling of bulk drugs, finished dosage formulations. The Agro Chemicals segment focuses on the manufacturing and selling of agro chemicals. It is also engaged in developing, manufacturing and marketing finished dosage formulations (FDF), active pharmaceutical ingredients (APIs) and intermediates. Its product portfolio consists of two categories of agrochemicals - pesticides and bioproducts. The key focus area is to fill the gaps in the portfolio through crop phenology analysis. It has manufacturing facilities in India which cater to both domestic and international markets.